AIMS: Late gadolinium enhanced cardiovascular magnetic resonance (LGE-CMR) is a valuable test to detect myocardial damage in patients with sarcoidosis; however, the clinical significance of LGE in sarcoidosis patients with preserved left ventricular ejection fraction (LVEF) is not defined. We aim to characterize the prevalence of LGE, its associated cardiac findings, and its clinical implications in sarcoidosis patients with preserved LVEF. METHODS AND RESULTS: One hundred and fifty-two patients with biopsy proven extra-cardiac sarcoidosis, no known cardiac sarcoidosis, and LVEF ≥ 50% referred for LGE-CMR were included in this observational study. The presence of LGE in the left ventricular myocardium was considered diagnostic for cardiac sarcoidosis. The cohort was divided into two groups based on the presence or absence of LGE. Twenty-nine patients (19%) had LGE involving 11 ± 9% of the left ventricle. The modified Japanese Ministry of Health and Welfare (JMHW) criteria for diagnosing cardiac sarcoidosis only had a sensitivity of 52% and specificity of 83% for identifying myocardial LGE in these patients. Compared with those patients without LGE, those with LGE had a higher heart rate (84 ± 19 vs. 76 ± 18 b.p.m., P= 0.002), greater prevalence of an abnormal electrocardiogram (76 vs. 31%, P< 0.001), diastolic dysfunction (67 vs. 33%, P= 0.05), reduced right ventricular ejection fraction (49 ± 8 vs. 55 ± 6%, P= 0.012), and evidence of non-sustained ventricular tachycardia (33 vs. 6%). CONCLUSIONS: In patients with sarcoidosis and preserved systolic function, myocardial damage is commonly present and may increase the risk of ventricular tachy-arrhythmias. The JMHW Criteria were neither sensitive nor specific for predicting the presence of myocardial LGE.
AIMS: Late gadolinium enhanced cardiovascular magnetic resonance (LGE-CMR) is a valuable test to detect myocardial damage in patients with sarcoidosis; however, the clinical significance of LGE in sarcoidosis patients with preserved left ventricular ejection fraction (LVEF) is not defined. We aim to characterize the prevalence of LGE, its associated cardiac findings, and its clinical implications in sarcoidosis patients with preserved LVEF. METHODS AND RESULTS: One hundred and fifty-two patients with biopsy proven extra-cardiac sarcoidosis, no known cardiac sarcoidosis, and LVEF ≥ 50% referred for LGE-CMR were included in this observational study. The presence of LGE in the left ventricular myocardium was considered diagnostic for cardiac sarcoidosis. The cohort was divided into two groups based on the presence or absence of LGE. Twenty-nine patients (19%) had LGE involving 11 ± 9% of the left ventricle. The modified Japanese Ministry of Health and Welfare (JMHW) criteria for diagnosing cardiac sarcoidosis only had a sensitivity of 52% and specificity of 83% for identifying myocardial LGE in these patients. Compared with those patients without LGE, those with LGE had a higher heart rate (84 ± 19 vs. 76 ± 18 b.p.m., P= 0.002), greater prevalence of an abnormal electrocardiogram (76 vs. 31%, P< 0.001), diastolic dysfunction (67 vs. 33%, P= 0.05), reduced right ventricular ejection fraction (49 ± 8 vs. 55 ± 6%, P= 0.012), and evidence of non-sustained ventricular tachycardia (33 vs. 6%). CONCLUSIONS: In patients with sarcoidosis and preserved systolic function, myocardial damage is commonly present and may increase the risk of ventricular tachy-arrhythmias. The JMHW Criteria were neither sensitive nor specific for predicting the presence of myocardial LGE.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: Jan-Peter Smedema; Gabriel Snoep; Marinus P G van Kroonenburgh; Robert-Jan van Geuns; Emiel C Cheriex; Anton P M Gorgels; Harry J G M Crijns Journal: Chest Date: 2005-09 Impact factor: 9.410
Authors: T Shimada; K Shimada; T Sakane; K Ochiai; H Tsukihashi; M Fukui; S Inoue; H Katoh; Y Murakami; Y Ishibashi; R Maruyama Journal: Am J Med Date: 2001-05 Impact factor: 4.965
Authors: B Y C Cheong; R Muthupillai; M Nemeth; B Lambert; D Dees; S Huber; R Castriotta; S D Flamm Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2009-07 Impact factor: 0.670
Authors: Dane Jefic; Binjou Joel; Eric Good; Fred Morady; Howard Rosman; Bradley Knight; Frank Bogun Journal: Heart Rhythm Date: 2008-10-30 Impact factor: 6.343
Authors: Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein Journal: Curr Treat Options Cardiovasc Med Date: 2017-01
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Patrizio Lancellotti; Fabien Hyafil; Ron Blankstein; Ronald G Schwartz; Wael A Jaber; Raymond Russell; Alessia Gimelli; François Rouzet; Marcus Hacker; Olivier Gheysens; Sven Plein; Edward J Miller; Sharmila Dorbala; Erwan Donal Journal: J Nucl Cardiol Date: 2018-02 Impact factor: 5.952
Authors: Chadi Ayoub; Elena Pena; Hiroshi Ohira; Alexander Dick; Eugene Leung; Pablo B Nery; David Birnie; Rob S B Beanlands Journal: Curr Cardiol Rep Date: 2015 Impact factor: 2.931
Authors: G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno Journal: JACC Cardiovasc Imaging Date: 2016-07-20
Authors: Gillian Murtagh; Luke J Laffin; Kershaw V Patel; Amit V Patel; Catherine A Bonham; Zoe Yu; Karima Addetia; Nadia El-Hangouche; Francesco Maffesanti; Victor Mor-Avi; D Kyle Hogarth; Nadera J Sweiss; John F Beshai; Roberto M Lang; Amit R Patel Journal: Echocardiography Date: 2016-09 Impact factor: 1.724
Authors: Edward Hulten; Saira Aslam; Michael Osborne; Siddique Abbasi; Marcio Sommer Bittencourt; Ron Blankstein Journal: Cardiovasc Diagn Ther Date: 2016-02